Form 4: AtriCure Insider Trades 5,000 Shares

AtriCure's Chief Scientific Officer, Vinayak Doraiswamy, reported the sale of 5,000 shares of common stock on May 15, 2026.

Summary

• Vinayak Doraiswamy, Chief Scientific Officer of AtriCure, Inc., reported a transaction on May 15, 2026.
• The transaction involved the sale of 5,000 shares of common stock at a price of $28.13 per share.
• Following this transaction, Doraiswamy beneficially owns 91,875 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard insider transaction without additional context that would suggest a significant positive or negative development for the company.

Negatives

• Insider selling of a significant number of shares can sometimes be interpreted negatively by the market, although the reasons for the sale are not specified.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The sale of shares by a Chief Scientific Officer at AtriCure, Inc. is a routine event that requires reporting under SEC regulations, providing transparency to the market regarding insider activity.

Stakeholder Impact

• Shareholders: The sale of shares by an insider may lead to questions about the insider's confidence in the company's future performance, though the specific reasons for the sale are not disclosed.
• Employees: As a standard disclosure, this filing is unlikely to have a direct impact on employees.
• Creditors: No direct impact expected.
• Customers: No direct impact expected.

Key Dates

Keywords

AtriCure, ATRC, Form 4, Insider Trading, Stock Sale, Beneficial Ownership, Securities Exchange Act